Cargando…

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

PURPOSE: Barasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML). The pharmacokinetic (PK),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dennis, Mike, Davies, Michelle, Oliver, Stuart, D’Souza, Roy, Pike, Laura, Stockman, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428523/ https://www.ncbi.nlm.nih.gov/pubmed/22864876 http://dx.doi.org/10.1007/s00280-012-1939-2

Ejemplares similares

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Structure of Aurora B–INCENP in complex with barasertib reveals a potential transinhibitory mechanism
por: Sessa, Fabio, et al.
Publicado: (2014)

Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
por: Krex, Dietmar, et al.
Publicado: (2023)

P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPA
por: Grundy, Martin, et al.
Publicado: (2011)

Barasertib: a novel approach for the treatment of metastatic melanoma
por: Azzariti, Amalia, et al.
Publicado: (2014)

A 1152 channel timing system for an electromagnetic calorimeter readout
por: Bonesini, M, et al.
Publicado: (1987)

1152. Characteristics of Patients with Invasive Infections Caused by Trichosporon asahii
por: Kim, Jinyeong, et al.
Publicado: (2020)

1152. Microbiology of Pediatric Neck Infections Based on Age and Anatomic Location
por: Dimo, Joana, et al.
Publicado: (2021)

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours
por: Johnson, Melissa L., et al.
Publicado: (2023)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

The Pharmacokinetics of The Biliary Excretion of Ciprofloxacin
por: Ball, C. S., et al.
Publicado: (1989)

Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation
por: Kerem, Eitan, et al.
Publicado: (2021)

HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152
por: Yeole, R. D., et al.
Publicado: (2008)

1152. Quantifying the health equity related public health impact of national immunisation programmes
por: Biundo, Eliana, et al.
Publicado: (2023)

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
por: Hartsink-Segers, S A, et al.
Publicado: (2013)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

The Aurora Kinases in Cell Cycle and Leukemia
por: Goldenson, Benjamin, et al.
Publicado: (2014)

Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells
por: Kim, Soo-Jeong, et al.
Publicado: (2012)

Pharmacokinetics, bioavailability, and excretion of ponazuril in piglets
por: Wang, Wenxiang, et al.
Publicado: (2022)

1152. Leveraging Human Factors Engineering to Optimize Low-level Disinfection of Bedside Medical Tools
por: Handy, Lori, et al.
Publicado: (2018)

1152. Implementation of Enhanced Data Surveillance Methods to Reduce Catheter-Associated Urinary Tract Infections
por: Ehni, Jordan, et al.
Publicado: (2019)

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
por: Tron, Adriana E., et al.
Publicado: (2018)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
por: Fathi, Amir T., et al.
Publicado: (2017)

Assessment of Echinococcus multilocularis surveillance reports submitted in 2017 in the context of Commission Regulation (EU) No 1152/2011
por: Beltrán‐Beck, Beatriz, et al.
Publicado: (2017)

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991
por: Goliaei, Ardeshir, et al.
Publicado: (2020)

Rho kinase inhibitors Y27632 and H1152 augment neurite extension in the presence of cultured Schwann cells
por: Fuentes, Erick O, et al.
Publicado: (2008)

The Advantage of a Total Knee Arthroplasty with Rotating Platform is Only Theoretical: Prospective Analysis of 1,152 Arthroplasties
por: Delport, H.P.
Publicado: (2013)

Retraction: Hydrogen Peroxide as an Effective Disinfectant for Pasteurella multocida. Yonsei Med J 2014;55:1152-6
por: Jung, In-Soo, et al.
Publicado: (2016)

Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2018 in the context of Commission Regulation (EU) No 1152/2011
por: Ciubotaru, Ramona Mihaela, et al.
Publicado: (2018)

Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
por: Hossain, Md Reduanul, et al.
Publicado: (2022)

On Excretion
por: Tidey, Stuart
Publicado: (1905)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Pharmacokinetics, tissue distribution, and excretion of zinc oxide nanoparticles
por: Baek, Miri, et al.
Publicado: (2012)

Pharmacokinetics, bioavailability, metabolism and excretion of δ-viniferin in rats
por: Mao, Ping, et al.
Publicado: (2016)

Pharmacokinetics and Excretion of Berberine and Its Nine Metabolites in Rats
por: Feng, Xinchi, et al.
Publicado: (2021)

Pharmacokinetics, bioavailability, tissue distribution and excretion of tangeretin in rat
por: Hung, Wei-Lun, et al.
Publicado: (2017)

Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation
por: de Oliveira, Fábio Morato, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ihcam2ut6l4l1jj93e0q3iau7i